Aspergillus fumigatus and aspergillosis: From basics to clinics

Area of Science:

• Medical Mycology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Aspergillus fumigatus is an airborne fungus causing invasive infections and high mortality, particularly in immunocompromised patients.
• Mould-active azoles are primary treatments for aspergillosis, but rising azole resistance threatens their efficacy.
• Emerging azole-resistant strains, including those with wild-type CYP51A, challenge current diagnostics and treatment options.

Purpose of the Study:

• To review the clinical challenges posed by Aspergillus fumigatus, focusing on the rise of azole resistance.
• To explore current and future strategies for diagnosing and treating invasive aspergillosis.
• To highlight the need for novel antifungal drugs and improved research models.

Main Methods:

• Comprehensive review of current literature on Aspergillus fumigatus infections and antifungal resistance.
• Analysis of diagnostic challenges, including the limitations of existing methods for detecting azole resistance.
• Discussion of therapeutic options, emerging resistance mechanisms, and the role of whole-genome sequencing.

Main Results:

• Azole resistance in Aspergillus fumigatus is a significant clinical problem, leading to treatment failures and increased mortality.
• Whole-genome sequencing is becoming crucial for identifying resistance mechanisms, especially in strains with wild-type CYP51A.
• Existing treatments like echinocandins and amphotericin B have limitations, necessitating new drug development.

Conclusions:

• Urgent development of novel antifungal agents and improved diagnostic tools is required to combat azole-resistant Aspergillus fumigatus.
• Further refinement of animal models and genetic engineering tools is essential for understanding resistance and host-pathogen interactions.
• Addressing the global challenge of invasive aspergillosis demands a multi-faceted approach including surveillance, diagnostics, and therapeutics.